GRFS

Grifols S.A.

Price

$7.46

return (12m)

-23.72%

p/e

9.84

p/bv

0.56

DIVIDEND YIELD

1.00%

GRFS price

Grifols

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment GRFS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-4.03%

3 months

-0.71%

1 year

-23.72%

2 years

-17.27%

5 years

-46.98%

10 years

-46.87%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals GRFS

Valuation

P/E

9.84

Sector -3.53

Industry -3.53

P/BV

0.56

Sector 2.06

Industry 2.06

P/Revenue (PSR)

0.60

Sector 2.02

Industry 2.02

EV/EBITDA

25.55

Sector -222.67

Industry -222.67

EV/EBIT

33.86

Sector -47.57

Industry -47.57

P/EBITDA

2.80

Sector -21.45

Industry -21.45

P/EBIT

3.87

Sector -28.49

Industry -28.49

P/Total Assets

0.22

Sector 1.20

Industry 1.20

P/Net Current Assets

-0.66

Sector -10.32

Industry -10.32

P/Working Capital

1.47

Sector -169.93

Industry -169.93

EPS

0.77

Sector -1.79

Industry -1.79

BVPS

13.50

Sector 2.05

Industry 2.05

Efficiency

Gross Margin

37.00%

Sector 41.30%

Industry 41.30%

EBITDA Margin

23.27%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

17.56%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

16.25%

Sector -35.21%

Industry -35.21%

Net Profit Margins

6.10%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.09

Sector 0.02

Industry 0.02

Profitability

ROE

5.73%

Sector -56.67%

Industry -56.67%

ROA

2.28%

Sector -59.91%

Industry -59.91%

ROIC

5.19%

Sector -2,349.21%

Industry -2,349.21%

Dividends

Dividend yield

1.00%

Sector -

Industry -

Payout

9.84%

Sector -

Industry -

Debt

Current Ratio

2.37

Sector 2.88

Industry 2.88

Net Debt / EBITDA

15.23

Sector -14,043,974.86

Industry -14,043,974.86

Net Debt / EBIT

20.18

Sector -8.02

Industry -8.02

Net Debt / Equity

0.83

Sector -32,936.86

Industry -32,936.86

Gross Debt / Equity

0.90

Sector -0.84

Industry -0.84

Equity/Assets

0.40

Sector 0.46

Industry 0.46

Liabilities/Assets

0.60

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

23.22%

Sector -

Industry -

5Y Earnings CAGR

10.52%

Sector -

Industry -

Fundamentals GRFS

DRAG THE FRAME TO SEE MORE DATA

FAIR VALUE OF Grifols ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$7.46

Fair Value

$15.29

Upside

105.14%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
GRFS Grifols S.A.	$7.46	-23.72%	1.00%	9.84	0.56	5.73%	6.10%
JNJ Johnson & Johnson	$264.37	51.83%	1.98%	30.47	7.54	24.76%	21.48%
PFE Pfizer Inc.	$27.50	23.30%	6.24%	35.93	1.84	5.11%	6.86%
ABBV AbbVie Inc.	$263.69	24.63%	2.65%	72.22	-76.87	-106.44%	9.81%
NVO Novo Nordisk A/S	$42.73	-19.34%	4.32%	10.50	5.58	53.11%	35.32%
MRK Merck & Co. Inc.	$143.48	80.02%	2.33%	112.32	8.48	7.55%	4.76%
AZN AstraZeneca PLC	$163.21	6.36%	2.03%	19.00	4.89	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$63.76	44.55%	3.96%	13.95	5.80	41.55%	18.85%
ZTS Zoetis Inc.	$73.56	-49.41%	2.89%	11.41	9.59	84.02%	27.77%
AMGN Amgen Inc.	$378.12	40.58%	2.25%	26.93	20.14	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$779.26	36.63%	0.47%	18.62	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$106.73	38.79%	0.00%	30.46	87.77	288.13%	24.86%
MCK McKesson Corporation	$896.58	26.67%	0.37%	19.68	-26.99	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$514.66	30.45%	0.00%	29.63	6.45	21.76%	35.00%
CAH Cardinal Health Inc.	$232.56	54.70%	0.88%	31.71	-20.07	-63.29%	0.68%
ARGX argenx SE	$994.76	31.52%	0.00%	2.61	3.00	114.60%	44.55%
HRMY Harmony Biosciences Holdings Inc.	$41.09	26.86%	0.00%	13.26	2.41	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

GRFS Historical Dividends

current DY: 1.00%

5-year average DY: 1.18%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	07/01/2026	07/09/2026	0.07650000
Dividends	08/11/2025	08/20/2025	0.17340000
Dividends	06/02/2021	06/14/2021	0.43850000
Dividends	10/29/2020	11/09/2020	0.20140000
Dividends	11/29/2019	12/11/2019	0.22190000
Dividends	06/06/2019	06/18/2019	0.16420000
Dividends	11/29/2018	12/11/2018	0.22780000
Dividends	05/31/2018	06/12/2018	0.25100000
Dividends	11/30/2017	12/12/2017	0.21270000
Dividends	05/30/2017	06/08/2017	0.16330000
Dividends	12/05/2016	12/14/2016	0.19340000
Dividends	06/02/2016	06/15/2016	0.16190000
Dividends	12/10/2015	12/17/2015	0.19220000
Dividends	06/08/2015	06/15/2015	0.16560000
Dividends	12/04/2014	12/12/2014	0.15450000
Dividends	06/05/2014	06/13/2014	0.14350000
Dividends	06/05/2013	06/13/2013	0.13040000
Dividends	05/24/2013	06/05/2013	0.006500

ABOUT Grifols

Grifols S.A.

Average Investor10 user rating

4.0 (4 people)

United States

39 years

Founded: 1987

2011

Time since IPO - 15 years

23.655

Employees

Grifols S.A. (United States) is listed on the Nasdaq and has a market capitalization of $5.19 billion, with shareholders equity totaling $9.19 billion.

The company employs approximately 23.655 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Grifols S.A. reported $8.63 billion in revenue, generating net income of $527.03 million.

Key financial metrics include a P/E ratio of 9.84, a price-to-book (P/B) ratio of 0.56, and a trailing twelve-month dividend yield of 1.00%.

The company trades under the ticker GRFS.

Market cap

$5.19 billion

Net worth

$9.19 billion

$9,193,550,000.00

Assets

$23.15 billion

$23,145,160,000.00

Total Shares Outstanding

681.00 million

681,000,000

Average Daily Trading Volume

$583.50 Thousand

$583,500.00

Sector

Health Care

Industry

Biotechnology

GRFS

GRFS revenue and profits

Financial Results GRFS

DRAG THE FRAME TO SEE MORE DATA

GRFS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$896.58 28,21% (12M)

P/E

19.68

0.37%

ROE

-137.16%

P/BV

-26.99

CAH - Cardinal Health

$232.56 56,73% (12M)

P/E

31.71

0.88%

ROE

-63.29%

P/BV

-20.07

JNJ - Johnson & Johnson

$264.37 52,40% (12M)

P/E

30.47

1.98%

ROE

24.76%

P/BV

7.54

ABBV - AbbVie

$263.69 25,04% (12M)

P/E

72.22

2.65%

ROE

-106.44%

P/BV

-76.87

MRK - Merck & Co.

$143.48 83,99% (12M)

P/E

112.32

2.33%

ROE

7.55%

P/BV

8.48

AZN - AstraZeneca

$163.21 7,03% (12M)

P/E

19.00

2.03%

ROE

25.77%

P/BV

4.89

PFE - Pfizer

$27.50 22,78% (12M)

P/E

35.93

6.24%

ROE

5.11%

P/BV

1.84

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$896.58 28,21% (12 M)

P/L

19.68

0.37%

ROE

-137.16%

P/VP

-26.99

CAH - Cardinal Health

$232.56 56,73% (12 M)

P/L

31.71

0.88%

ROE

-63.29%

P/VP

-20.07

JNJ - Johnson & Johnson

$264.37 52,40% (12 M)

P/L

30.47

1.98%

ROE

24.76%

P/VP

7.54

ABBV - AbbVie

$263.69 25,04% (12 M)

P/L

72.22

2.65%

ROE

-106.44%

P/VP

-76.87

MRK - Merck & Co.

$143.48 83,99% (12 M)

P/L

112.32

2.33%

ROE

7.55%

P/VP

8.48

AZN - AstraZeneca

$163.21 7,03% (12 M)

P/L

19.00

2.03%

ROE

25.77%

P/VP

4.89

PFE - Pfizer

$27.50 22,78% (12 M)

P/L

35.93

6.24%

ROE

5.11%

P/VP

1.84

Frequently Asked Questions

What is the price of Grifols (GRFS) today?

A cotação de Grifols (GRFS) hoje está em US$ 7.46, com uma variação de -23.72% em relação ao último ano. A cotação de Grifols (GRFS) iniciou o ano negociando na casa dos US$ 9.35 e hoje está em US$ 7.46. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Grifols (GRFS) e dados de ações do Ibovespa e mercados internacionais.

Quando Grifols (GRFS) paga dividendos?

No último ano, Grifols (GRFS) distribuiu dividendos no mês de July, totalizando US$ 0.08. O Dividend Yield referente aos 12 últimos meses é de 1.00%.

Is Grifols (GRFS) a good investment?

Atualmente, Grifols (GRFS) está cotada a US$ 7.46, com um P/L de 9.84, representando um desvio de 2,697% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -23.72 em sua cotação e distribuiu US$ 0.08 em dividendos, resultando em um Dividend Yield de 1.00%. O retorno total do acionista foi de -23.72%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Grifols (GRFS) stock?

Investir em ações de Grifols (GRFS) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Grifols (GRFS) yield today?

A rentabilidade de Grifols (GRFS) foi de -4.03% no último mês, -23.72% no último ano e -46.98% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.08 em dividendos, um Dividend Yield de 1.00%.

Se você quisesse comprar 100 ações de Grifols (GRFS) hoje, o investimento total seria de US$ 745.50, com base na cotação atual de US$ 7.46.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 568.67
Em 5 anos: US$ 395.26
Em 10 anos: US$ 396.08

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

GRFS

Grifols S.A.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment GRFS

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

Graham's Fair Value

COMPARING GRFS WITH OTHER STOCK

current DY: 1.00%

5-year average DY: 1.18%

type

Ex - Dividend Date

payment date

value

ABOUT Grifols

Grifols S.A.

United States

39 years

2011

23.655

PROFIT X PRICE GRFS

Financial Results GRFS

GRFS cash flow

Asset, Revenue and Profit Growth - GRFS

GRFS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions